GI-301

Mergers & Acquisitions Korea Zinc to sell $301 mn in CPs amid management feud with MBK

Korea Zinc Inc., the world’s top zinc and lead smelter, is set to sell 400 billion won ($300.9 million) in commercial papers, its first fundra...

Bio & Pharma GI Innovation transfers allergy treatment tech to Japan

South Korea's GI Innovation Inc. announced on Monday it has transferred its allergy treatment "GI-301" to the Japanese pharmaceutical company Maruho...

Bio & Pharma GI Innovation seeks to license allergy therapy to Japan in 2023

South Korea’s GI Innovation Inc. aims to complete licensing of its allergic diseases treatment candidate to a Japanese drug company by year's ...

IPOs S.Korean biotech GI Innovation's IPO draws tepid market interest

South Korean biotech GI Innovation Inc. is slated to debut on the local public market at less than half of its pre-IPO investment value, facing luke...

Bio & Pharma GI Cell wins approval for human cell management from Korean regulator

GI Cell, a South Korean developer of immune cell therapy products, received a human cell and others management license from South Korean regulatory,...

Bio & Pharma S. Korea's GI Cell, Japanese partner to study cell therapy for blood cancer

South Korea's GI Cell, the cell therapy affiliate of GI Innovation, on Tuesday said it signed an agreement with Optieum Biotechnologies of Japan on ...